URGN - UroGen Pharma Ltd Stock Price, Fair Value and News

13.28USD+0.07 (+0.53%)Delayed as of 17 May 2024, 11:59 am ET

Market Summary

USD13.28+0.07

Delayedas of 17 May 2024, 11:59 am

0.53%

URGN Alerts

Losses in recent quarter

URGN Stock Price

View Fullscreen

URGN RSI Chart

URGN Valuation

Market Cap

477.3M

Price/Earnings (Trailing)

-4.58

Price/Sales (Trailing)

5.66

EV/EBITDA

-4.45

Price/Free Cashflow

-5.79

URGN Price/Sales (Trailing)

URGN Profitability

Operating Margin

89.53%

EBT Margin

-119.05%

Return on Equity

259.92%

Return on Assets

-52.01%

Free Cashflow Yield

-17.28%

URGN Fundamentals

URGN Revenue

Revenue (TTM)

84.3M

Rev. Growth (Yr)

9.24%

Rev. Growth (Qtr)

-20.18%

URGN Earnings

Earnings (TTM)

-104.3M

Earnings Growth (Yr)

-6.86%

Earnings Growth (Qtr)

-24.1%

Breaking Down URGN Revenue

52 Week Range

8.6924.13

(Low)(High)

Last 7 days

1.8%

Last 30 days

-8.9%

Last 90 days

-31.7%

Trailing 12 Months

10.9%

How does URGN drawdown profile look like?

URGN Financial Health

Current Ratio

7.47

Debt/Equity

-2.43

Debt/Cashflow

-0.84

URGN Investor Care

Shares Dilution (1Y)

54.05%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	84.3M	0	0	0
2023	68.0M	72.5M	77.3M	82.7M
2022	54.1M	57.7M	62.4M	64.4M
2021	19.3M	31.9M	39.8M	48.0M
2020	7.2M	8.8M	10.3M	11.8M
2019	0	2.7M	4.2M	5.7M
2018	8.6M	9.0M	1.5M	1.1M
2017	15.2M	12.8M	10.5M	8.2M
2016	0	0	0	17.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of UroGen Pharma Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	schoenberg mark	sold	-168,600	14.05	-12,000	chief medical officer
Feb 01, 2024	schoenberg mark	sold	-59,790	15.78	-3,789	chief medical officer
Feb 01, 2024	smith jason drew	sold	-78,789	15.78	-4,993	general counsel
Jan 31, 2024	schoenberg mark	acquired	-	-	6,666	chief medical officer
Jan 31, 2024	kim dong	acquired	-	-	3,333	chief financial officer
Jan 31, 2024	smith jason drew	acquired	-	-	10,000	general counsel
Jan 31, 2024	schoenberg mark	sold	-59,638	15.74	-3,789	chief medical officer
Jan 31, 2024	smith jason drew	sold	-78,589	15.74	-4,993	general counsel
Aug 31, 2023	smith jason drew	sold	-68,438	18.01	-3,800	general counsel

Which funds bought or sold URGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	HSBC HOLDINGS PLC	new	-	794,310	794,310	-%
May 15, 2024	Soleus Capital Management, L.P.	new	-	150,000	150,000	0.01%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-50.09	-1,080,940	1,077,240	-%
May 15, 2024	BARCLAYS PLC	reduced	-48.05	-269,000	291,000	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-21.08	-417,000	1,561,500	0.01%
May 15, 2024	PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO	unchanged	-	-	21,000	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	reduced	-53.57	-450	390	-%
May 15, 2024	Vivaldi Capital Management LP	added	22.25	-52,264	256,380	0.07%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	new	-	4,008,000	4,008,000	-%
May 15, 2024	FIRST MANHATTAN CO. LLC.	unchanged	-	-	22,500	-%

Are Funds Buying or Selling URGN?

Are funds buying URGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own URGN

No. of Funds

URGN Alerts

Losses in recent quarter

Unveiling UroGen Pharma Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 08, 2024	blackrock inc.	4.6%	1,669,543	SC 13G/A
Feb 22, 2024	arkin moshe	4.44%	1,369,315	SC 13D/A
Feb 14, 2024	rtw investments, lp	5.6%	1,726,808	SC 13G
Feb 14, 2024	menora mivtachim holdings ltd.	7.46%	2,303,031	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	9.99%	3,083,558	SC 13G/A
Feb 14, 2024	great point partners llc	8.49%	2,620,545	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	0%	0	SC 13G/A
Feb 02, 2024	blackrock inc.	5.6%	1,719,304	SC 13G
Dec 29, 2023	ra capital management, l.p.	9.99%	3,083,550	SC 13G
Sep 15, 2023	great point partners llc	8.51%	2,620,545	SC 13G

Recent SEC filings of UroGen Pharma Ltd

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 08, 2024	SC 13G/A	Major Ownership Report
Apr 29, 2024	10-K/A	Annual Report
Mar 20, 2024	4	Insider Trading
Mar 18, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	10-K	Annual Report
Mar 14, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Mar 01, 2024	8-K	Current Report

Peers (Alternatives to UroGen Pharma Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

UroGen Pharma Ltd News

Latest updates

UroGen Pharma Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	-20.2%	18,781,000	23,530,000	20,852,000	21,139,000	17,192,000	18,092,000	16,097,000	16,604,000	13,564,000	16,174,000	11,351,000	13,032,000	7,485,000	7,966,000	3,461,000	372,000	297,600	223,200	148,800	74,400	-
Cost Of Revenue	-24.4%	1,728,000	2,286,000	2,367,000	2,443,000	2,265,000	2,263,000	2,020,000	1,846,000	1,525,000	1,589,000	1,244,000	1,427,000	897,000	652,000	309,000	48,000	-	-	-	-	-
Gross Profit	-19.7%	17,053,000	21,244,000	18,485,000	18,696,000	14,927,000	15,829,000	14,077,000	14,758,000	12,039,000	14,585,000	10,107,000	11,605,000	6,588,000	7,314,000	3,152,000	324,000	-	-	-	18,000	-
S&GA Expenses	11.2%	27,299,000	24,551,000	21,755,000	22,494,000	24,474,000	21,634,000	19,071,000	20,833,000	21,300,000	21,418,000	21,624,000	22,304,000	22,189,000	22,163,000	22,065,000	24,018,000	21,973,000	19,745,000	13,972,000	13,775,000	12,552,000
R&D Expenses	37.1%	15,494,000	11,302,000	10,230,000	11,584,000	12,498,000	14,477,000	13,093,000	12,640,000	12,696,000	13,082,000	11,923,000	12,124,000	10,513,000	12,405,000	10,211,000	8,106,000	16,588,000	20,094,000	9,481,000	9,996,000	11,465,000
EBITDA Margin	-0.3%	-1.18	-1.18	-1.34	-1.47	-1.61	-1.66	-1.70	-1.93	-2.04	-2.26	-2.72	-3.36	-5.85	-	-	-	-	-	-	-	-
Income Taxes	-98.6%	54,000	3,854,000	-9,000	54,000	21,000	689,000	709,000	32,000	325,000	1,137,000	-	312,000	-	3,374,000	-	-	-	-	-	-	-
Earnings Before Taxes	-45.4%	-32,232,000	-22,162,000	-21,888,000	-24,082,000	-30,192,000	-28,180,000	-25,122,000	-26,659,000	-28,067,000	-27,315,000	-30,211,000	-25,910,000	-25,935,000	-27,152,000	-28,816,000	-31,349,000	-	-	-	-	-
EBT Margin	-0.2%	-1.19	-1.19	-1.35	-1.48	-1.62	-1.68	-1.72	-1.95	-2.06	-2.28	-2.74	-3.38	-5.87	-	-	-	-	-	-	-	-
Net Income	-24.1%	-32,286,000	-26,016,000	-21,879,000	-24,136,000	-30,213,000	-28,869,000	-25,831,000	-26,691,000	-28,392,000	-28,452,000	-30,211,000	-26,222,000	-25,935,000	-30,526,000	-28,816,000	-31,349,000	-37,793,000	-38,973,000	-22,252,000	-22,477,000	-23,716,000
Net Income Margin	-0.1%	-1.24	-1.24	-1.36	-1.50	-1.64	-1.71	-1.75	-1.97	-2.09	-2.31	-2.83	-3.49	-6.05	-	-	-	-	-	-	-	-
Free Cashflow	-143.1%	-31,735,000	-13,052,000	-17,399,000	-20,289,000	-25,830,000	-21,765,000	-17,765,000	-24,262,000	-24,021,000	-20,272,000	-18,670,000	-19,014,000	-27,688,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	12.5%	201	178	194	95.00	113	136	128	146	166	120	135	154	97.00	122	140	161	167	202	227	239	252
Current Assets	16.3%	197	169	182	81.00	96.00	129	122	140	161	114	125	140	93.00	116	129	130	122	149	160	191	248
Cash Equivalents	38.4%	131	95.00	119	20.00	37.00	55.00	29.00	81.00	105	44.00	55.00	63.00	40.00	53.00	25.00	36.00	26.00	50.00	66.00	90.00	247
Inventory	27.7%	7.00	6.00	5.00	5.00	5.00	4.00	5.00	5.00	5.00	5.00	4.00	3.00	3.00	2.00	1.00	1.00	-	-	-	-	-
Net PPE	-17.9%	1.00	1.00	1.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-1.2%	241	244	236	234	230	225	192	187	183	111	103	97.00	21.00	26.00	19.00	18.00	16.00	22.00	16.00	14.00	12.00
Current Liabilities	-15.6%	26.00	31.00	26.00	27.00	25.00	24.00	19.00	18.00	19.00	22.00	20.00	19.00	17.00	21.00	18.00	16.00	14.00	19.00	14.00	12.00	10.00
Long Term Debt	-1.0%	98.00	99.00	99.00	98.00	98.00	98.00	72.00	71.00	71.00	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	99.00	99.00	98.00	98.00	98.00	72.00	71.00	71.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	38.5%	-40.13	-65.21	-	-	-116	-89.36	-	-	-	8.00	32.00	56.00	76.00	96.00	121	143	150	180	211	225	240
Retained Earnings	-4.8%	-711	-679	-653	-631	-607	-577	-548	-522	-495	-467	-438	-408	-382	-356	-325	-297	-265	-228	-189	-166	-144
Additional Paid-In Capital	9.3%	671	614	611	493	491	488	485	481	479	476	470	465	459	453	446	439	416	408	400	391	384
Shares Outstanding	11.2%	36.00	32.00	31.00	24.00	23.00	23.00	23.00	23.00	23.00	22.00	22.00	22.00	22.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	190	-	-	-	145	-	-	-	251	-	-	-	525	-	-	-	695	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-144.2%	-31,735	-12,996	-17,299	-20,274	-25,807	-21,752	-17,612	-24,199	-23,996	-20,070	-18,476	-18,945	-27,401	-21,242	-25,080	-23,929	-35,635	-26,000	-12,528	-14,555	-17,934
Share Based Compensation	5.6%	2,756	2,611	2,224	2,222	2,286	2,368	2,440	2,823	2,949	5,357	5,515	6,046	6,195	6,526	6,763	7,119	7,617	8,065	7,243	7,212	7,447
Cashflow From Investing	219.2%	13,518	-11,344	401	3,720	6,270	23,108	-35,493	-151	13,596	9,125	10,660	-30,740	15,024	49,465	13,234	17,514	13,025	9,296	-12,659	-142,186	-44.00
Cashflow From Financing	136542.5%	54,657	40.00	116,077	143	671	25,368	1,101	-77.00	70,742	-32.00	-168	72,515	4.00	78.00	61.00	16,298	90.00	245	1,126	373	163,506

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

URGN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue	$ 18,781	$ 17,192
Cost of revenue	1,728	2,265
Gross profit	17,053	14,927
Operating expenses:
Research and development expenses	15,494	12,498
Selling, general and administrative expenses	27,299	24,474
Operating loss	(25,740)	(22,045)
Financing on prepaid forward obligation	(5,660)	(5,224)
Interest expense on long-term debt	(2,447)	(3,553)
Interest and other income, net	1,615	630
Loss before income taxes	(32,232)	(30,192)
Income tax expense	(54)	(21)
Net Loss	(32,286)	(30,213)
Statements of Comprehensive Loss
Net loss	(32,286)	(30,213)
Other comprehensive income (loss)
Unrealized gain (loss) on investments	(49)	62
Comprehensive Loss	$ (32,335)	$ (30,151)
Net loss per ordinary share - basic and diluted (in dollars per share)	$ (0.97)	$ (1.3)
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)	33,379,786	23,279,951

URGN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 131,439	$ 95,002
Marketable securities	32,606	41,966
Restricted cash	823	821
Accounts receivable	14,158	15,443
Inventories	7,243	5,673
Prepaid expenses and other current assets	10,491	10,281
Total current assets	196,760	169,186
Non-current assets:
Property and equipment, net	566	689
Restricted deposit	226	225
Right of use assets	1,443	1,671
Marketable securities	481	4,502
Other non-current assets	1,098	2,038
Total Assets	200,574	178,311
Current liabilities:
Accounts payable and accrued expenses	18,158	16,538
Employee related accrued expenses	4,985	10,814
Other current liabilities	3,197	3,860
Total current liabilities:	26,340	31,212
Non-current liabilities:
Prepaid forward obligation	112,947	109,722
Long-term debt	97,590	98,551
Long-term lease liabilities	637	844
Uncertain tax positions liability	3,194	3,194
Total Liabilities	240,708	243,523
Commitments and Contingencies (Note 18)
Shareholders' Deficit:
Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 36,127,687 and 32,490,119 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	99	89
Additional paid-in capital	671,438	614,035
Accumulated deficit	(711,634)	(679,348)
Accumulated other comprehensive loss	(37)	12
Total Shareholders' Deficit	(40,134)	(65,212)
Total Liabilities and Shareholders' Deficit	$ 200,574	$ 178,311

About UroGen Pharma Ltd

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

CEO	Ms. Elizabeth A. Barrett
WEBSITE	urogen.com
INDUSTRY	Biotechnology
EMPLOYEES	193

UroGen Pharma Ltd Frequently Asked Questions

What is the ticker symbol for UroGen Pharma Ltd? What does URGN stand for in stocks?

URGN is the stock ticker symbol of UroGen Pharma Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of UroGen Pharma Ltd (URGN)?

As of Thu May 16 2024, market cap of UroGen Pharma Ltd is 477.28 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers.

What is the fair value of URGN stock?

You can check URGN's fair value in chart for subscribers. The fair value of UroGen Pharma Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of UroGen Pharma Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for URGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is UroGen Pharma Ltd a good stock to buy?

The fair value guage provides a quick view whether URGN is over valued or under valued. Whether UroGen Pharma Ltd is cheap or expensive depends on the assumptions which impact UroGen Pharma Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for URGN.

What is UroGen Pharma Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, URGN's PE ratio (Price to Earnings) is -4.58 and Price to Sales (PS) ratio is 5.66. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. URGN PE ratio will change depending on the future growth rate expectations of investors.